Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis reports positive trial data for cancer drug Zaltrap

Sanofi-aventis reports positive trial data for cancer drug Zaltrap

28th April 2011

Sanofi-aventis has published clinical trial data that highlights the efficacy of its developmental cancer therapy Zaltrap.

In association with partner Regeneron Pharmaceuticals, the company has conducted a phase III study called Velour, which trialled the drug as a second-line treatment for metastatic colorectal cancer in combination with a chemotherapy regimen.

Results from the trial showed that Zaltrap was able to meet its primary efficacy goal of improving overall survival compared to chemotherapy plus placebo.

This comes as part of a wider collaborative research programme for the promising cancer therapy, which also includes a second phase III trial and a phase II study, both of which are fully enrolled.

Dr Debasish Roychowdhury, senior vice-president and head of the global oncology division at Sanofi-aventis, said: "We are committed to bringing Zaltrap to patients with advanced colorectal cancer and maximising the therapeutic potential of this unique and exciting medicine."

Earlier this month, the company announced that it will be allying with Stanford University's Bio-X programme to conduct early-stage scientific research.ADNFCR-8000103-ID-800514546-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.